Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Cabozantinib CAS 849217-68-1

Cabozantinib CAS 849217-68-1

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 849217-68-1

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
849217-68-1
Appearance::
White Powder
Molecular Formula::
C28H24FN3O5
Molecular Weight::
501.50600
EINECS NO::
692-846-8
MDL NO::
MFCD20926324
CAS NO::
849217-68-1
Appearance::
White Powder
Molecular Formula::
C28H24FN3O5
Molecular Weight::
501.50600
EINECS NO::
692-846-8
MDL NO::
MFCD20926324
Cabozantinib CAS 849217-68-1

Product Description:

Product Name: Cabozantinib CAS NO: 849217-68-1

 

 

 

Synonyms:

[14C]-Cabozantinib;

Cometriq;

 

 

 

Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.0%

Density: 1.397 g/cm3

Boiling Point: 758.075℃ at 760 mmHg

Flash Point: 412.269℃

Refractive Index: 1.688

 

 

 

Safety Information:

HS Code: 2933499090

 

 

Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.